{"filing":{"accession_number":"0001104659-26-072326","cik":"0001689375","ticker":"TRDA","company_name":"Entrada Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"tm2617532d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465926072326/tm2617532d1_8k.htm"},"events":[{"id":5597,"run_id":4911,"accession_number":"0001104659-26-072326","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Entrada Therapeutics held its Annual Meeting of stockholders on June 10, 2026, with shareholders voting on four proposals: election of two Class II directors (Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D.), ratification of Ernst \u0026 Young LLP as independent auditor, and approval of Amendment No. 1 to both the 2021 Stock Option and Incentive Plan and the 2021 Employee Stock Purchase Plan. All proposals passed with clear majorities.","company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5828,"accession_number":"0001104659-26-072326","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on stockholder approval of Amendment No. 1 to the 2021 Stock Option and Incentive Plan and Amendment No. 1 to the 2021 Employee Stock Purchase Plan, both of which modify the evergreen provisions affecting the total shares available for equity compensation. These are compensatory arrangements affecting the equity incentive plans available to directors and officers, making this an exec_compensation event. The amendments are material as they expand the pool of shares available for future equity grants by including pre-funded warrants in the evergreen calculation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:08:14.880213+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5829,"accession_number":"0001104659-26-072326","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the final results of an Annual Meeting of stockholders held on June 10, 2026. The filing presents voting outcomes for four proposals: election of two Class II directors (Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D.), ratification of Ernst \u0026 Young LLP as independent auditor, approval of the 2021 Plan Amendment, and approval of the 2021 ESPP Amendment. All proposals passed with clear majorities. Shareholder vote results are material to investors as they confirm governance and compensation decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:08:14.880213+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5828,"accession_number":"0001104659-26-072326","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on stockholder approval of Amendment No. 1 to the 2021 Stock Option and Incentive Plan and Amendment No. 1 to the 2021 Employee Stock Purchase Plan, both of which modify the evergreen provisions affecting the total shares available for equity compensation. These are compensatory arrangements affecting the equity incentive plans available to directors and officers, making this an exec_compensation event. The amendments are material as they expand the pool of shares available for future equity grants by including pre-funded warrants in the evergreen calculation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:08:14.880213+00:00","company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","filing_date":"2026-06-10"},{"id":5829,"accession_number":"0001104659-26-072326","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the final results of an Annual Meeting of stockholders held on June 10, 2026. The filing presents voting outcomes for four proposals: election of two Class II directors (Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D.), ratification of Ernst \u0026 Young LLP as independent auditor, approval of the 2021 Plan Amendment, and approval of the 2021 ESPP Amendment. All proposals passed with clear majorities. Shareholder vote results are material to investors as they confirm governance and compensation decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:08:14.880213+00:00","company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","filing_date":"2026-06-10"}]}